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Abstract
Background: Patients with human papillomavirus-positive (HPV+) oropharyngeal squamous cell carcinoma (OPC)
have substantially better treatment response and overall survival (OS) than patients with HPV-negative disease.
Treatment options for HPV+ OPC can involve either a primary radiotherapy (RT) approach (± concomitant
chemotherapy) or a primary surgical approach (± adjuvant radiation) with transoral surgery (TOS). These two
treatment paradigms have different spectrums of toxicity. The goals of this study are to assess the OS of two de-
escalation approaches (primary radiotherapy and primary TOS) compared to historical control, and to compare
survival, toxicity and quality of life (QOL) profiles between the two approaches.
Methods: This is a multicenter phase II study randomizing one hundred and forty patients with T1–2 N0–2 HPV+
OPC in a 1:1 ratio between de-escalated primary radiotherapy (60 Gy) ± concomitant chemotherapy and TOS ± de-
escalated adjuvant radiotherapy (50–60 Gy based on risk factors). Patients will be stratified based on smoking status
(< 10 vs. ≥ 10 pack-years). The primary endpoint is OS of each arm compared to historical control; we hypothesize
that a 2-year OS of 85% or greater will be achieved. Secondary endpoints include progression free survival, QOL
and toxicity.
Discussion: This study will provide an assessment of two de-escalation approaches to the treatment of HPV+ OPC
on oncologic outcomes, QOL and toxicity. Results will inform the design of future definitive phase III trials.
(Continued on next page)
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Background
Oropharyngeal squamous cell carcinoma (OPC) is rap-
idly increasing in incidence, associated with rising rates
of human papillomavirus (HPV) infection [1, 2]. Patients
with HPV-positive (HPV+) OPC have substantially bet-
ter treatment response and overall survival (OS) than pa-
tients with HPV-negative (HPV-) disease [3]. Historically
the management of OPC has relied on radiotherapy
(RT) based approaches as older surgical techniques re-
quired large incisions and mandibulotomies with high
surgical morbidity and mortality [4]. The addition of
concurrent chemotherapy to radiation improved onco-
logical outcomes [5]. However, acute and long term side
effects of RT or chemoradiation (CRT) can be severe, in-
cluding frequent swallowing dysfunction, mucositis, xer-
ostomia, fibrosis, osteoradionecrosis, neutropenia,
neurotoxicity and hearing loss [6].
The introduction of minimally invasive transoral surgi-
cal techniques including transoral robotic surgery (TORS)
and transoral laser microsurgery (TLM) has led to a re-
vival of surgery as the primary treatment of OPC [7, 8].
While primary surgery with transoral surgery (TOS) can
avoid some of the side effects of radiotherapy, it can have
rare serious consequences such as fatal hemorrhage,
stroke, shoulder dysfunction and dysphagia [9].
Currently, there is no level I evidence to favor one treat-
ment strategy over the other. Instead, treatment selection
is largely driven by institutional and patient biases with
the majority of patients in the United States receiving sur-
gery (82% of T1-T2 disease) [7], while most patients re-
ceive primary RT in Canada and Europe [10, 11].
The ORATOR trial is the only trial to examine the
question of a primary RT vs. primary TOS approach in a
randomized fashion [12]. This phase II trial included 68
patients with OPC regardless of HPV status, and ran-
domized patients to RT (70 Gy, with chemotherapy if
N1–2) or TOS plus neck dissection (with or without ad-
juvant RT/CRT, based on pathology). The primary end-
point was swallowing-related quality of life (QOL) at 1
year, measured using the MD Anderson Dysphagia In-
ventory (MDADI) [13]. The study found that at 1 year
there was a statistically significant difference in swallow-
ing QOL but that this difference did not represent a
clinically meaningful change (less than a 10-point
difference).
Since the ORATOR trial opened in 2012, the land-
scape has further shifted to recognize the clinical im-
portance of HPV status. The impact of HPV on
outcomes has been so substantial that a separate staging
system has been created to better represent the progno-
sis of these patients [3, 14]. Although not yet part of
routine clinical care, research is now focused on de-
intensification of treatment in HPV+ OPC, in an attempt
to reduce adverse events while maintaining excellent on-
cologic outcomes. Patients with HPV-related OPC have
an excellent chance of survival, and therefore may have
to deal with the sequelae of therapy for many decades
[3]. With excellent rates of cure, post-treatment QOL
becomes of paramount importance. Trials focusing on
both primary RT and primary surgical approaches have
de-escalated radiotherapy doses; two key trials that are
currently underway include NRG-HN-002 and ECOG-
3311 [15, 16].
NRG-HN-002 [15] included 308 patients in a phase II
parallel-arm design investigating de-intensification in a
low-risk p16+ population (T1–2N1-N2b or T3 N0-N2b
as per AJCC 7th edition, and ≤ 10 pack-year smoking his-
tory). Arm 1 was conventionally fractionated CRT with
60Gy (2 Gy/fraction) given in 6 weeks with weekly cis-
platin 40mg/m2 and Arm 2 was accelerated RT alone with
60Gy (2 Gy/fraction) given in 5 weeks with 6 fractions per
week. The trial had co-primary endpoints with
progression-free survival (PFS) and QOL at 2 years with
acceptability criterion of PFS of ≥85% and an MDADI
score ≥ 60. Early results presented in abstract format
showed the CRT arm met the acceptability criteria for
both PFS and MDADI, while the accelerated radiotherapy
arm did not meet the PFS acceptability criterion [15].
ECOG-3311 focuses on a primary surgical approach
for cT1–2 N1–2b (as per AJCC 7th edition) HPV+ OPC
patients, de-escalating the adjuvant RT dose for inter-
mediate risk patients based on surgical pathology. After
resection, if a patient has any of: close margins, < 1mm
of extranodal extension (ENE), 2–4 lymph nodes (LN)
involved, perineural invasion (PNI) or lymphovascular
invasion (LVI) they are randomized in a 1:1 ratio to
standard dose adjuvant RT (60 Gy) or de-escalated adju-
vant RT (50 Gy). The primary endpoint for this trial is
PFS. This trial has completed accrual, but results are not
yet reported [16].
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Given the dramatic rise in the incidence of HPV dis-
ease and the paucity of high-quality data comparing
treatment options, the management of HPV+ OPC is ar-
guably the most contentious issue in head and neck on-
cology [17, 18]. The purpose of this randomized trial is
to assess the safety of two de-escalation approaches (pri-
mary RT and primary surgery) in early T stage HPV+
OPC by comparing to historical control, and to compare
survival, toxicity and QOL profiles between the two ap-
proaches. The primary radiotherapy approach is based
on the chemoradiation arm of HN002, and the primary
surgery approach is based on the treatment paradigm of
ECOG-3311 [15, 16].
Methods/design
The objectives of this trial are to:
1. Compare OS relative to historical controls for de-
intensified primary radiotherapy [60 Gy ± chemo-
therapy] versus TOS and neck dissection [± adju-
vant 50 Gy radiotherapy] in patients with early T-
stage HPV+ squamous cell carcinoma of the
oropharynx.
2. Compare PFS, toxicity and QOL profiles.
Our hypothesis is that for patients with HPV+ T1–
2N0–2 (as per AJCC 8th edition) OPC, de-intensified
primary RT and primary surgery with de-intensified ad-
juvant therapy will achieve 2-year OS rates of 85% or
greater.
Study design
This study is an open-label phase II multi-centre ran-
domized trial, and is designed to assess two potential
treatment de-escalation approaches, comparing each to
a historical control, with the potential goal of evaluating
one or both compared to standard CRT in a subsequent
phase III trial. The required sample size is 140 patients.
Participating centres will be tertiary, academic hospitals
or radiotherapy treatment centres in Canada (updated
list of participating centres available on clinicaltrials.gov:
identifier NCT03210103). Patients will be randomized
between a primary RT-based approach (Arm 1) vs. a pri-
mary surgical approach (Arm 2) in a 1:1 ratio using a
permutated block design (Fig. 1). There will be one
stratification factor: smoking status (< 10 vs. ≥ 10 pack-
years). Arm 1 of this trial is based on the chemoradia-
tion arm of HN002 (60 Gy ± concomitant weekly cis-
platin based on clinical nodal disease) [15], and Arm 2 is
similar to the treatment paradigm of ECOG-3311




Defined as time from randomization to death
from any cause
This study was originally launched with a primary end-
point of PFS. The results of the original ORATOR trial
became available in February 2019. These suggested that
OS would be a preferred endpoint for ORATOR2 as
both arms in ORATOR showed excellent OS in p16+
cancers (both > 92% at 2 years). OS is preferred as the
primary endpoint to evaluate de-escalation, since it was
evident in ORATOR that progression events, whether
local, regional, or distant, can often be salvaged for cure
Fig. 1 Study Schema
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with surgery, radiation, or systemic therapy including
immunotherapy. Therefore, in Feb 2019, without know-
ledge of outcomes data from ORATOR2, this trial was
amended to promote OS from a secondary to primary
endpoint, and demote PFS to a secondary endpoint.
Secondary endpoints
 2-year PFS (comparison with historical controls)
Time from randomization to disease
progression at any site or death PFS events are
defined as death from any cause, or first
recurrence of tumor at any site (including local,
regional, or distant). Second primary tumors (e.g.
head and neck cancer at a different site, such as
laryngeal cancer) will not be included as PFS
events.
 2-year OS and PFS comparisons between Arm 1 and
Arm 2
 Swallowing-related QOL at 1-year post-treatment
Assessed using the MDADI
 QOL at other time points
Assessed using the MDADI, the European
Organisation for Research and Treatment of
Cancer (EORTC) Quality of Life Cancer Patients
general (QLQ-C30) and head & neck (H&N35)
scales, the Voice Handicap Index (VHI-10), the
Neck Dissection Impairment Index (NDII), the
Patient Neurotoxicity Questionnaire (PNQ), and
the EuroQOL 5-Dimension 5-Level (EQ-5D-5 L).
 Toxicity
Assessed by the National Cancer Institute
Common Toxicity Criteria (NCI-CTC) version 4
 Other functional measurements, including,
measured by:
Feeding tube rate at 1-year
Common Toxicity Criteria for Adverse Events
(CTC-AE) Dysphagia scores
Inclusion criteria
 Minimum age 18
 Willing to provide informed consent
 Eastern Cooperative Oncology Group (ECOG)
performance status 0–2
 Histologically confirmed squamous cell carcinoma
 HPV+ tumor, as determined by: positive p16 status,
real-time polymerase chain reaction (PCR) or in-situ
hybridization. Central confirmation is not required.
 Primary tumor site in the oropharynx (includes
tonsil, base of tongue, soft palate, walls of
oropharynx)
 Eligible for curative intent treatment, with likely
negative resection margins at surgery. For patients
where adequate transoral access is in question, they
will first have an examination under anesthesia
ensure adequate exposure can be obtained prior to
randomization.
 Smokers and non-smokers are included. Patients will
be stratified by < 10 versus ≥10 pack-year smoking
history. Pack-years are calculated by multiplying the
number of years smoked by the number of packs of
cigarettes smoked per day. One pack is considered
to contain 20 cigarettes.
 Tumor stage (AJCC 8th edition): T1 or T2
 Nodal stage (AJCC 8th edition): N0, N1 or N2
 For patients who may require chemotherapy (i.e.
patients with multiple lymph nodes positive or a
single node more than 3 cm in size, in any plane; see
section 6): complete blood count/differential
obtained within 4 weeks prior to randomization,
with adequate bone marrow function, hepatic, and
renal function, defined as: Absolute neutrophil count
> 1.5 × 109/L; Hemoglobin > 80 g/L; platelets > 100 ×
109/L; Bilirubin < 35 μmol/L; AST, ALT < 3 x the
upper limit of normal; serum creatinine < 130 μmol/
L or creatinine clearance ≥50 mL/min
 Head and neck multidisciplinary clinic (radiation
oncologist and surgeon) and multidisciplinary tumor
board presentation prior to randomization.
Exclusion criteria
 Unambiguous clinical or radiological evidence of
ENE on pre-treatment imaging. This includes the
presence of matted nodes, defined as 3 or more
nodes that are abutting with loss of intervening fat
planes.
 Serious medical comorbidities or other
contraindications to RT, surgery or chemotherapy
 Inability to attend full course of RT or follow-up
visits
 History of previous head and neck RT or previous
head and neck cancer within 5 years
 Metastatic disease present
 Prior invasive malignant disease within 5 years, with
the exception of non-melanoma skin cancer
 Lactating or pregnant women
Pre-treatment evaluation
The following evaluations are required:
 History and physical examination (including
laryngopharyngoscopy) by a radiation oncologist and
head and neck surgeon within 8 weeks prior to
randomization
 For patients where adequate transoral access is in
question, they will have an examination under
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anesthesia to ensure adequate exposure can be
obtained prior to randomization
 Staging imaging within 12 weeks prior to
randomization: Contrast-enhanced CT of the neck
and chest or MRI of the neck with CT of the chest
or whole body PET/CT
 Documentation of smoking history
 Histological confirmation of squamous cell
carcinoma
 p16+ or HPV+ tumor status, as defined above
 Dental evaluation within 6 weeks prior to
randomization
 Audiogram before initiation of treatment, with
baseline CTCAE grade assessment
 Assessment of all baseline symptoms, including
assessment of dysphagia, using CTC-AE version 4
within 2 weeks prior to randomization. Baseline dys-
phagia CTC-AE will be scored in all patients.
 Completion of QOL scoring within 2 weeks of
randomization
 CBC/differential, hepatic (AST, ALT, total bilirubin)
and renal function testing (BUN and creatinine, or
creatinine clearance) within 4 weeks prior to
randomization, if chemotherapy would be required
 Pregnancy test for women of child-bearing age,
within 2 weeks prior to randomization
 Blood sample for whole genome sequencing analysis
prior to initiation of treatment
 Informed consents must be obtained prior to any
study specific activities
Interventions
Initiation of treatment should occur within 4 weeks of
randomization.
Primary radiotherapy (Arm 1)
Treatment in this arm is generally based on Arm 1 of
NRG-HN002 [15], and may consist of either radiotherapy
alone or concurrent chemoradiation depending on the pa-
tient’s clinical nodal status (see Table 1).
Dose levels are as follows:
 60 Gy in 30 fractions: Gross Tumor and Involved
Nodes
 54 Gy in 30 fractions: High risk subclinical areas.
 48 Gy in 30 fractions: Low-risk nodal areas
Specific radiotherapy volume definitions for Arm 1 are
described in Table 2. In all cases a 5 mm CTV to PTV
expansion is to be used.
Treatment breaks, early RT termination and discon-
tinuation of systemic therapy is at the discretion of
the treating oncologist based on patient treatment
toxicity.
Salvage surgery Treatment response will be evaluated
10–12 weeks after completion of RT. This can be done
using a CT scan and/or a PET-CT scan.
Treatment of residual disease at the site of the primary
tumor will be determined by the treating physicians, and
should include surgical salvage if feasible.
Management of residual enlarged lymph nodes in the
neck should be guided by standard institutional practice.
In general, for patients with residual enlarged nodes on
CT, a PET-CT is preferred to confirm fluorodeoxyglu-
cose (FDG) avidity prior to neck dissection. If the PET-
CT is negative in the setting of enlarged nodes on CT,
then close interval follow-up with repeat CT every 2–3
months is recommended until the lymph nodes resolve.
If PET-CT is unavailable, any nodes > 1 cm in short axis
should, at a minimum, be carefully followed with repeat
CT every 2–3 months until the lymph nodes resolve,
with neck dissection at the discretion of the treating
physician.
Salvage surgery for the primary tumor or lymph nodes
within 5months of treatment will be considered part of
the initial treatment package and scored as persistent
Table 1 Delivery of radiation ± chemotherapy depending on clinical nodal status in Arm 1 (Primary RT)
Radiation Alone: Accelerated radiation Concurrent chemotherapy: Weekly cisplatin 40mg/m2 for 6 cycles
Nodal status Node negative (N0)
OR




Single lymph node more
than 3 cm in maximal diameter
Fractionation Radiation over 5 weeks, with
6 fractions a week
6th weekly fraction given on
a weekday with a minimum 6 h
intrafraction interval, or on a Saturday
Daily radiation, Monday-Friday
over 6 weeks
Special conditions In patients > 70 years of age, standard
fractionation (daily, Monday-Friday over
6 weeks) can be used at the discretion
of the radiation oncologist
In patients who are deemed unfit
for weekly cisplatin, the dose and/or
schedule can be modified, or cetuximab
or weekly carboplatin AUC 1.5 can be used,
at the discretion of the medical oncologist.
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disease, not as recurrence. Surgery beyond 5months post-
treatment will be scored as recurrence if malignancy is
evident in the pathology specimen.
Primary TOS (Arm 2)
Patients with easily accessible oropharyngeal tumors (de-
termined by the consulting surgeon), will proceed dir-
ectly to TOS. If adequate transoral access is in question,
patients will undergo an examination under anesthesia
to ensure adequate exposure can be obtained prior to
randomization.
Surgical resection will be carried out with at least 1
cm margins. At the time of surgery circumferential
margins will be taken and sent for frozen section.
The resection will be revised until negative margins
are obtained if feasible. Wounds may be closed by
primary closure, local flaps (i.e. buccal or palatal
flaps) or allowed to heal by secondary intention at
the discretion of the treating surgeons. Free flap and
regional flaps are not allowed.
Standard selective neck dissections for the lymph node
areas at risk will be performed at the time of transoral
resection, or as a staged procedure 2 weeks prior to the
primary site resection. At this time the lingual and facial
branches of the ipsilateral external carotid artery must
be ligated on the side ipsilateral to the primary tumor.
Patients with tonsillar, lateral palate and lateral
pharyngeal cancers, with < 1 cm of base of tongue or pal-
ate extension, will undergo ipsilateral neck dissections
only. All other patients will undergo bilateral neck dis-
sections. Selective neck dissections will be limited to
levels 2–4, unless levels 1 or 5 are involved.
If there is a positive margin at the time of TOS at the
primary site, an attempt to clear the positive margin
transorally will be allowed. If a positive or close margin
is found on the final pathology from the transoral resec-
tion, an attempt to clear the margin transorally is
allowed within 4 weeks of the original TOS resection.
This can be done with or without the robot at the sur-
geon’s discretion.
A tracheostomy is strongly recommended, but not
mandatory, to provide airway protection in the event of
swelling and/or bleeding.
Adjuvant radiotherapy Adjuvant radiotherapy will be
determined based on pathological findings. No more
than 6 weeks should elapse between the date of surgery
and the initiation of adjuvant therapy.
Adjuvant radiotherapy is required for the following
risk factors:
 ENE
 Positive margins or close resection margins (< 3
mm)
 More than 1 lymph node positive, or any lymph
node > 3 cm in size on pathology
 LVI
 pT3–4 disease
In situations where PNI alone is present, without the
other risk factors above, adjuvant RT is at the discretion
of the treating physicians.
Table 2 Specific RT volume definition volumes for Arm 1
(Primary RT)
Radiotherapy Volume Definition
GTV_P Gross tumour volume
GTV_N Gross nodes:
– > 1.5 cm long axis
– > 1 cm short axis
– Necrotic
– PET positive
CTV60 Combination of GTV_P




CTV54 – A 1 cm expansion on
the GTV_P
– Any nodal level that
contains a
positive node.




disease. This node plus
an additional 5 mm margin
will be
included in the CTV54.
– The first echelon draining
nodal levels. This is nearly
always level 2, but should
include the lateral retropharyngeal
nodes (RP) for soft palate and
posterior pharyngeal wall
extension.
CTV48 – Patients that are node negative:
Ipsilateral: II-IV. RP only if
extension to posterior pharyngeal
wall or soft palate
Contralaterala: II-IV, RP only if
extension to posterior pharyngeal
wall or soft palate
– All patients with N1 (ipsilateral)
nodal disease:
Ipsilateral: Ib, II-V, RP
Contralaterala: II-IV, RP only if
extension to
posterior pharyngeal wall or soft
palate
– All patients with N2 disease:
Ipsilateral and contralateral:
Ib, II-V, RP
aIf treating the contralateral neck
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Patients with positive margins or ENE will receive a 6-
week course of radiation as follows:
 60 Gy in 30 fractions: Area of positive margins or
ENE
 54 Gy in 30 fractions: Operative bed, including
primary tumor location and all dissected nodal levels
 48 Gy in 30 fractions: Undissected areas considered
to be at low-risk of harbouring microscopic disease.
Patients without positive margins or ENE will receive
a 5-week course of radiation as follows:
 50 Gy in 25 fractions: Operative bed, including
primary tumor location and all dissected nodal levels
 45 Gy in 25 fractions: Undissected areas considered
to be at low-risk of harbouring microscopic disease.
Concurrent chemoradiation will not be delivered in
the adjuvant setting unless gross tumor is left behind at
the primary site or in the neck AND the patient would
have received chemotherapy had they been randomized
to Arm 1. Chemotherapy is NOT used for patients with
ENE or positive margins. Retrospective surgical data do
not support an OS benefit to the use of chemotherapy in
HPV+ patients with ENE [19].
Specific radiotherapy volume definitions for Arm 2 are
described in Table 3. In all cases a 5 mm CTV to PTV
expansion is to be used.
The AJCC 8th edition has a pathologically based
staging system for HPV+ patients treated with pri-
mary surgery that differs significantly from the clinic-
ally based staging system used for patients treated
with primary radiation. All surgically treated patients
will be separately re-staged after the final pathology is
available.
In the unlikely event of residual gross disease, the pa-
tient should then receive adjuvant treatment using the
dose fractionations in Arm 1. In the unlikely scenario
where a patient is deemed to have highly aggressive dis-
ease (e.g. frank growth/progression during the post-
surgical interval), the radiation oncologist may elect to
treat with a standard (non-de-escalated) dose of 70 Gy in
35 fractions. Treatment breaks, early RT termination
and discontinuation of systemic therapy is at the discre-
tion of the treating oncologist based on patient treat-
ment toxicity.
Unilateral vs. Bilateral radiation
Unilateral radiation is recommended if the following cri-
teria are ALL met:
 tonsil primary
 < 1 cm extension into the tongue base or palate
 no posterior pharyngeal wall extension
 no ENE
 N0, or only a single ipsilateral lymph node positive
Unilateral radiation is optional if the following criteria
are ALL met
 tonsil primary
 < 1 cm extension into the tongue base or palate
 no posterior pharyngeal wall extension
 no ENE
 more than one ipsilateral lymph node positive, but
are all less than 6 cm, and are all in level II.
In all other cases, bilateral radiation is mandatory.
These criteria apply to all patients in Arm 1, and to
patients in Arm 2 who require adjuvant RT. For the
patients in Arm 2 who receive adjuvant RT, these cri-
teria are based on the pathological findings and
Table 3 Specific RT volume definition volumes for Arm 2
(Primary TOS) if adjuvant RT is required
Radiotherapy Volume Definition








CTV60 Areas of positive margins
and/or ENE
CTV54 CTV50 Entire tumor bed and any
dissected neck nodal
levels
CTV48 CTV45 Undissected nodal areas







nodes (eg. if there is a
level II node positive,
levels Ib and V must be
included)















aIf treating the contralateral neck
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intraoperative findings, not the pre-operative clinical
findings.
Radiotherapy technique, immobilization, localization and
planning
Intensity modulated radiotherapy (IMRT) will be used
for all patients in this study. IMRT can be delivered
using static-beam techniques or rotational techniques
(e.g. Tomotherapy or Volumetric Modulated Arc Ther-
apy [VMAT]). A custom thermoplastic shell will be used
to immobilize all patients. Patients will then undergo a
planning CT simulation (head and neck to below the
clavicles, slice thickness 3 mm or less.) Patients in Arm 1
will receive contrast (unless contraindicated). For pa-
tients in both arms, when necessary, the planning CT
will be fused with other diagnostic imaging).
Organ at risk (OAR) contouring definitions, dose con-
straints and planning priorities are shown in Add-
itional file 1, adapted from RTOG protocols 1016 [20]
(Arm 1) and 0920 [21] (Arm 2), HN-002 [15], ECOG-
3311 [16] and the NCIC-CTG HN6 protocol [22]. Dose
constraints are the same whether 25 or 30 fractions are
delivered, as the radiobiological conversion factor is
small.
Plans will be normalized to ensure that 95% of each
PTV is covered by 100% of the prescription dose for that
volume. 99% of each PTV must receive at least 93% of
the prescription dose. The maximum dose must be less
than 115% of the highest prescription dose.
Quality assurance
Radiotherapy quality assurance
A quality assurance protocol is used to ensure safe and
efficacious treatment with the following elements
present for each patient:
 Discussion of each radiotherapy plan at head and
neck quality assurance (QA) rounds prior to, or
within the first week of treatment
 Physics staff will confirm all dose delivery for IMRT
plans (including arc-based treatments) before
treatment.
 Cone-beam CT and/or orthogonal x-rays will be
used daily to verify treatment positioning, as per in-
stitutional standard practice.
 Prior to enrolling patients, each centre will be given
a sample CT dataset for contouring, planning and
physics QA. Enrollment can begin once the plan and
QA have been approved at the London Regional
Cancer Program (LRCP).
Surgery quality assurance
The learning curve for surgeons carrying out transoral
oropharyngeal cancer resections has been demonstrated
to be short for early-stage cases, with significant im-
provements in operative time after 20 cases (but not on-
cologic outcomes) as learning occurs [23]. Surgeons will
be required to complete a “Surgical Credentialing Ques-
tionnaire” based closely on the ECOG-3311 credential-
ing criteria (Additional file 2). This includes 1) being
fellowship trained in head and neck surgical oncology, 2)
having carried out at least 20 transoral oropharyngeal
cancer resections as primary surgeon, 3) providing op-
erative notes for 10 of those cases, 4) a minimum of 5
oropharyngeal resections in the last year and 5) perform
at least 30 neck dissections per year.
Individual surgeons will be reviewed for surgical qual-
ity after every 5 surgical cases by the principal investiga-
tor (AN). Bleeding or positive margin rates of greater
than 20% may result in exclusion from the trial at the
discretion of the principal investigators. The occurrence
of an oropharyngeal bleeding fatality or severe anoxic
brain injury in the absence of a tracheostomy may also
result in the exclusion of the centre from the trial.
Centres will be reviewed for surgical quality after 5, 10
and 15 surgical cases by the principal investigators.
Bleeding or positive margin rates of greater than 20%
may result in exclusion from the trial at the discretion of
the principal investigators. The occurrence of an oropha-
ryngeal bleeding fatality or severe anoxic brain injury in
the absence of a tracheostomy may also result in the ex-
clusion of the centre from the trial.
Pathology reporting of ENE: The electronic case report
forms must include a description of ENE using the same
descripTOS as the ECOG-3311 trial:
 absent (node without metastasis or nodal metastasis
with smooth/rounded leading edge confined to
thickened capsule/pseudocapsule)
 minimal (tumor extends ≤1 mm beyond the lymph
node capsule)
 present - extensive (tumor extends > 1 mm beyond
the lymph node capsule (includes soft tissue
metastasis))
Subject discontinuation / withdrawal
Subjects may voluntarily discontinue participation in the
study at any time. If a subject is removed from the study,
the clinical and laboratory evaluations that would have
been performed at the end of the study should be ob-
tained. If a subject is removed because of an adverse
event, they should remain under medical observation as
long as deemed appropriate by the treating physician.
Follow-up evaluation
Day 1 of follow-up will be the first day of radiotherapy
(Arm 1) or the date of surgery (Arm 2); however, sur-
vival will be calculated from the date of randomization.
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The follow-up schedule is summarized in Add-
itional file 3, and is the same as the follow-up schedule
of ORATOR [24]. On Arm 1 patients will be seen during
treatment, for a post-treatment clinical assessment at 4–
6 weeks. Post-treatment imaging with a CT or PET/CT
of the neck will be obtained. On Arm 2 a post-operative
assessment will occur at 2 weeks with adjuvant radio-
therapy beginning within 6 weeks of surgery if required.
If radiotherapy is delivered the same treatment and
post-treatment assessments will occur as on Arm 1, A
return visit with the surgeon will occur at 3 months from
the date of surgery. On both arms patients will be seen
every 3 months up to 2 years and then every 6months
thereafter (up to 5 years) from the start of treatment,
with clinical, toxicity and QOL assessments (Additional
file 3). For patients in both arms, a CT of the neck, and
chest, MRI of the neck with CT of the chest or whole
body PET/CT will be obtained at 12 months. Additional
imaging or laboratory investigations and additional treat-
ment (eg. Salvage treatment) will be carried out at the
discretion of the treating physicians.
Disease progression and new primary
In the event of disease progression, the details of new or
recurrent disease and treatment details will be captured
in the case report form. Audiologic assessments, blood-
work and QOL questionnaires should continue to be
completed according to the follow up schedule (Add-
itional file 3). All ongoing adverse events (AEs) at the
time of progression should be followed until resolution.
Subsequent imaging after progression can be completed
at the discretion of the treating investigator.
Salvage surgery after primary radiotherapy Treatment
of residual disease at the site of the primary tumor will
be determined by the treating physicians, and should in-
clude surgical salvage if feasible.
Management of residual enlarged lymph nodes in the
neck should be guided by standard institutional practice.
In general, for patients with residual enlarged nodes on
CT, a PET-CT is preferred to confirm FDG avidity prior
to neck dissection. If the PET-CT is negative in the set-
ting of enlarged nodes on CT, then close interval follow-
up with repeat CT every 2–3 months is recommended
until the lymph nodes resolve. If PET-CT is unavailable,
any nodes > 1 cm in short axis should, at a minimum, be
carefully followed with repeat CT every 2–3 months
until the lymph nodes resolve, with neck dissection at
the discretion of the treating physician.
Salvage surgery for the primary tumor or lymph nodes
within 5 months of treatment will be considered part of
the initial treatment package and scored as persistent
disease, not as recurrence. Surgery beyond 5months
post-treatment will be scored as recurrence if malig-
nancy is evident in the pathology specimen.
Measurement of outcomes
 Survival outcomes:
OS: time from randomization until death from
any cause
PFS: time from randomization to either
progression or death, whichever occurs first.
 QOL outcomes (measured at baseline and at 6-
month intervals except PNQ):
MDADI
EORTC QLQ-C30 and H&N35 scales
NDII
VHI-10
PNQ will be completed at 1 year post-
treatment.
 Economic assessment:
EQ-5D-5 L: administered at baseline and 6
month intervals. Quality adjusted life years
(QALYs) will be assessed as the area under the
preference-weighted survival curve. Overall costs
of each treatment strategy will be abstracted from
the available literature. The incremental cost ef-
fectiveness ratios (ICERs) between treatment arms
will be compared through the standard method of
ratio between differences in costs and QALYs.
Point estimates for these differences can be de-
rived from multivariable generalized estimating
equations (GEE) or general linear model (GLM)
analyses.
 Toxicity outcomes:
CTC-AE toxicities will be recorded during
treatment and at every follow-up visit.
Statistical considerations
Randomization
Patients will be randomized between Arm 1: Arm 2
stratified based on smoking status (< 10 pack-years vs.
≥10 years) in a 1:1 ratio in a permutated block design.
The randomization sequence is known only to the statis-
tician and uploaded into a restricted-access database
(REDCap) housed on secure hospital servers at LHSC
[25]. Upon enrollment of a patient, the database will be
accessed by the trial coordinator to obtain the next
intervention in the random sequence, for the pertinent
stratum, which will then be assigned to the patient.
Sample size calculation
The 2-year OS in each arm, based on the results of
ORATOR, is estimated to be 94%. A 2-year OS of < 85%
will be considered inadequate. In order to differentiate
an OS of 94% vs. 84% using a 1-sided one-sample
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binomial test, with 80% power and alpha of 0.05, with
10% dropout, 70 patients are needed in each arm (140
total).
Analysis plan
Patients will be analyzed in the groups to which they are
assigned (intention-to-treat). Comparisons of OS and
PFS with historical controls will be evaluated using a
one-sided binomial test. The 2-year PFS in this cohort is
estimated to be approximately 85%, based on the results
of CCTG HN6 [22]. If the 2-year PFS is < 75%, it will be
considered unacceptable. Therefore, PFS in each arm
will be compared against a benchmark PFS of 74%. A
comparison of OS and PFS between the two treatment
arms will also be conducted, using the stratified log-rank
test (stratified by smoking pack-year history). With a
sample size of 140 patients, we will have 80% power to
detect a 10% superiority in OS in either arm (assuming
baseline OS of 94% in whichever arm is superior), using
a two-sided alpha of 0.05. A two-sample T-test will be
used to compare QOL scores at 1-year (excluding PNQ).
The percentage of patients in each arm who experience
a clinically significant QOL decline (10 points) will also
be reported. Pre-planned subgroup analysis will occur
based on the stratification variable (smoking pack-year
history). A Cox proportional hazards multivariable re-
gression analysis will be used to determine baseline fac-
tors predictive of survival. QOL analysis for secondary
endpoints will be performed in the same way as the
ORATOR trial using linear mixed-effects models [24].
The original ORATOR trial will be used for additional
historical controls [12]. A comparison will occur be-
tween HPV+ patients in ORATOR (who were treated
with more aggressive approaches) and ORATOR2 to as-
sess differences in QOL and time-to-event outcomes.
Data safety monitoring committee
The data safety monitoring committee (DSMC), consist-
ing of at least one surgical oncologist, one radiation on-
cologist, and one medical oncologist not involved in the
study and without competing interests, will meet bi-
annually after study initiation to review toxicity out-
comes. The DSMC can recommend modification of the
trial based on toxicity outcomes.
After half of the patients are enrolled and followed for
6 months, one interim analysis will take place. For this
interim analysis, OS at 2-years will be calculated for each
arm. The DSMC may recommend cessation or modifica-
tion of the trial if any of these two criteria are met:
1. The rate of grade 5 toxicity definitely related to
treatment is > 5% in either arm
2. The upper bound of the 95% confidence interval of
OS at 2 years does not include 94%.
Biomarker studies
All of the biomarker studies described in this section
will be performed in Dr. Anthony Nichols’ laboratory
located at the London Regional Cancer Program, in
London, Ontario. All specimens will be labeled solely
with the patient’s unique study identifier number,
stored in a secure facility at London Health Sciences
Centre (LHSC), and will be accessed only by clinical
trial staff. Details are provided in Additional file 4.
Ten mL of blood shall be drawn pre-operatively into
a heparinized (green top) tube and directly trans-
ported to Dr. Nichols’ lab. At the end of the study
pre-treatment formalin fixed paraffin embedded
(FFPE) primary site biopsy specimens will be retrieved
in 10 slides 8 μm thick as well as three 1 mm core
punch biopsies from the FFPE blocks and transported
to Dr. Nichols’ lab. For patients treated at the lead
centre (LRCP) and randomized to primary surgery a
fresh frozen specimen will be collected. Specifically, at
the time of operation the main specimen will be
taken to pathology frozen section room and a portion
from the center of the specimen will be taken with
the assistance of the pathologist and frozen at − 80
degrees Celsius. This will be transported to Dr.
Nichols’ lab.
Human papillomavirus testing P16 testing (which is an
excellent surrogate marker of HPV status) is required
for enrollment. This will be done through the routine
pathology laboratories as per current routine clinical
care. The accompanying biomarker study will determine
HPV status by real-time PCR, not for the purposes of
randomization, but to confirm the accuracy of p16 re-
sults and also for subtyping of HPV strain. Pre-
treatment FFPE primary site biopsy specimens will be
retrieved in 10 slides 8 μm thick from the FFPE blocks.
DNA will be extracted from the specimens for HPV test-
ing by real-time PCR.
Whole genome sequencing analysis DNA will be ex-
tracted either from fresh tumor or from formalin fixed
specimens for patients undergoing TOS, as well as 10
mL of venous blood drawn prior to the initiation of
treatment. Specimens yielding DNA of adequate quan-
tity and quality (> 5 μg, OD between 1.8 and 2.0) will be
subjected to high-throughput sequencing and gene copy
number.
Ethical considerations
The Principal Investigator will obtain ethical approval
and clinical trial authorization by competent authorities
according to local laws and regulations.
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Institutional Review Board (IRB) / Research Ethics Board
(REB)
The protocol (and any amendments), the informed con-
sent form, and any other written information to be given
to subjects will be reviewed and approved by a properly
constituted Institutional Review Board (IRB)/Research
Ethics Board (REB), operating in accordance with the
current federal regulations (e.g., Canadian Food and
Drug Regulations (C.05.001); US Code of Federal Regu-
lations (21CFR part 56)), ICH GCP and local regulatory
requirements. A letter to the investigator documenting
the date of the approval of the protocol and informed
consent form will be obtained from the IRB/REB prior
to initiating the study. Any institution opening this study
will obtain REB IRB/REB approval prior to local
initiation.
Informed consent
The written informed consent form is to be provided to
potential study subjects (Additional file 5) should be ap-
proved by the IRB/REB and adhere to ICH GCP and the
ethical principles that have their origin in the Declar-
ation of Helsinki. The investigator is responsible for
obtaining written informed consent from each subject,
or if the subject is unable to provide informed consent,
the subject’s legally acceptable representative, prior to
beginning any study procedures and treatment(s). The
investigator should inform the subject, or the subject’s
legally acceptable representative, of all aspects of the
study, including the potential risks and benefits involved.
The subject will be given ample time and opportunity to
ask questions prior to deciding about participating in the
study and be informed that participation in the study is
voluntary and that they are completely free to refuse to
enter the study or to withdraw from it at any time, for
any reason.
The informed consent will be signed and dated by the
subject, or the subject’s legally acceptable representative,
and by the person who conducted the informed consent
discussion. A copy of the signed and dated written in-
formed consent form will be given to the subject or the
subject’s legally acceptable representative. The process
of obtaining informed consent will be documented in
the patient source documents.
Confidentiality
The names and personal information of study partici-
pants will be held in strict confidence. All study records
(CRFs, safety reports, correspondence, etc.) will only
identify the subject by initials and the assigned study
identification number. The data coordinator will main-
tain a confidential subject identification list (Master List)
during the course of the study. Access to confidential in-
formation (i.e., source documents and patient records) is
only permitted for direct subject management and for
those involved in monitoring the conduct of the study
(i.e., Sponsors, CRO’s, representatives of the IRB/REB,
and regulatory agencies). The subject’s name will not be
used in any public report of the study.
Data storage
All data will be stored on REDCap [25] a secure web ap-
plication for building and managing online databases
commonly used in the clinical trials research commu-
nity. Ongoing auditing will be performed by the LRCP
clinical trials unit, independent from the trial investiga-
tors and sponsor. All of the biomarker studies described
in this section will be performed in Dr. Anthony
Nichols’ laboratory located at the LRCP, in London, On-
tario. All specimens will be labeled solely with the pa-
tient’s unique study identifier number, stored in a secure
facility at LHSC, and will be accessed only by clinical
trial staff.
Adverse events
The severity of adverse events will be evaluated using
the Common Terminology Criteria for Adverse Events
(CTCAE) version 4.0 grading scale [26]. Any grade 4 or
5 adverse event that is definitely, probably, or possibly
the result of protocol treatment must be reported to the
Principal Investigator and Central Office within 24 h of
discovery. The Serious Adverse Event (SAE) report form
is to be completed with all available information and
uploaded to the REDCap SAE page. The Central Office
must be notified by email or telephone that a new SAE
form has been uploaded into REDCap. It is the responsi-
bility of each local Principal Investigator to report all
SAEs to their REB as per local REB requirements. The
Principal Investigator should also comply with the ap-
plicable regulatory requirement(s) related to the report-
ing of unexpected serious adverse drug reactions to the
regulatory authority (ies).
Data sharing statement
De-identified participant data from this trial will not be
shared publicly, however, the full protocol will be pub-
lished along with the primary analysis of the outcomes.
Protocol ammendments and trial publication
Trial registration elements are summarized in Add-
itional file 6. Any modifications to the trial protocol
must be approved and enacted by the principal investi-
gator (Current version: 1.3 on March 15, 2019). Protocol
amendments will communicated to all participating cen-
tres, investigators, IRBs, and trial registries by the princi-
pal investigator. Any communication or publication of
trial results will be led by the principal investigator, and
is expected to occur within 1 year of the primary
Nichols et al. BMC Cancer          (2020) 20:125 Page 11 of 13
analysis. Trial results will remain embargoed until con-
ference presentation of an abstract or until information
release is authorized. Authorship of the trial abstract
and ultimately the full manuscript will be decided by the
principal investigator at the time of submission. Profes-
sional writers will not be used for either abstract or
manuscript preparation.
Discussion
Patients with HPV+ OPC have substantially better treat-
ment response and OS than HPV- disease [3]. This has
spurred increasing interest in de-escalation of therapy
with the hopes of reducing treatment-related toxicity.
ORATOR2 is a multi-center phase II trial that aims to
randomize 140 patients to two de-escalated interven-
tions: de-escalated radiotherapy (± chemotherapy) or
TOS (± adjuvant radiotherapy). The primary radiother-
apy arm is based on the chemoradiation arm of HN002
[15] and the TOS arm is partially based on the treatment
paradigm of ECOG-3311 [16].
This trial will assess the safety of both of these de-
escalation approaches, comparing each to historical con-
trols, and will allow for comparisons of OS, PFS and
QOL between the two interventions. There is a paucity
of data comparing primary RT and primary surgical ap-
proaches to oropharyngeal cancers. To date, the only
randomized study examining this question is ORATOR,
which enrolled patients regardless of HPV status, and in-
cluded a small number of patients. ORATOR2 will allow
for an assessment of both approaches in the early T-
stage HPV+ patient population. Furthermore, the ORA-
TOR trial can be used for additional historical controls,
with a planned comparison between HPV+ patients in
ORATOR (who were treated with more aggressive ap-
proaches) and ORATOR2 to assess differences in QOL
and time-to-event outcomes.
A recruitment video has been created to help patients
and the public understand the rationale and design be-
hind the trial, and to help reach the target accrual (www.
orator2.com).
Results of ORATOR2 are expected to provide data
that will help guide treatment decisions in the manage-
ment of HPV-associated OPC, which remains one of the
most contentious issues in head and neck oncology.
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